Payment overview · 2025
General Payments
$460.07
19 reported records · 10 companies
Healthcare provider profile · identity verified
Robert Theodore Toborg, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · WINSTON-SALEM, NC · NPI 1003813650
Verified facts
What the public records show
CMS Open Payments records show Robert Theodore Toborg, M.D. received $460.07 in general payments during 2025 across 19 reported records.
AstraZeneca Pharmaceuticals LP accounted for 36.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $168.87 | 36.7% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $66.15 | 14.4% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $51.04 | 11.1% | 3 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $44.23 | 9.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $37.34 | 8.1% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $21.87 | 4.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.42 | 4.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.26 | 4.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.43 | 3.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.46 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $460.07 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $138.93 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $66.15 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $51.04 | 3 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $44.23 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $37.34 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.19 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.26 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 119 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 62 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
60 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
45 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
119 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
119 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
117 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 781 | 217 |
| Levothyroxine Sodium | Levothyroxine Sodium | 477 | 110 |
| Lisinopril | Lisinopril | 438 | 122 |
| Amlodipine Besylate | Amlodipine Besylate | 409 | 116 |
| Hydrochlorothiazide | Hydrochlorothiazide | 346 | 100 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 310 | 85 |
| Losartan Potassium | Losartan Potassium | 292 | 86 |
| Omeprazole | Omeprazole | 290 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 258 | 73 |
| Gabapentin | Gabapentin | 219 | 57 |
| Metformin Hcl | Metformin Hcl | 214 | 62 |
| Alprazolam | Alprazolam | 205 | 47 |
| Furosemide | Furosemide | 201 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 190 | 48 |
| Simvastatin | Simvastatin | 188 | 53 |
| Ezetimibe | Ezetimibe | 159 | 44 |
| Tramadol Hcl | Tramadol Hcl | 151 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 148 | 55 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 144 | 59 |
| Trazodone Hcl | Trazodone Hcl | 142 | 38 |
| Potassium Chloride | Potassium Chloride | 139 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 137 | 39 |
| Meloxicam | Meloxicam | 134 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 129 | 32 |
| Eliquis | Apixaban | 124 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 122 | 36 |
| Jardiance | Empagliflozin | 119 | 27 |
| Ozempic | Semaglutide | 117 | 22 |
| Bupropion Xl | Bupropion Hcl | 112 | 23 |
| Metformin Hcl Er | Metformin Hcl | 111 | 33 |
| Sertraline Hcl | Sertraline Hcl | 105 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 103 | 26 |
| Prednisone | Prednisone | 102 | 83 |
| Citalopram Hbr | Citalopram Hydrobromide | 99 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 97 | 29 |
| Montelukast Sodium | Montelukast Sodium | 91 | 25 |
| Carvedilol | Carvedilol | 89 | 28 |
| Baclofen | Baclofen | 87 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 87 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 84 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 82 | 21 |
| Allopurinol | Allopurinol | 81 | 25 |
| Finasteride | Finasteride | 79 | 20 |
| Alendronate Sodium | Alendronate Sodium | 78 | 22 |
| Celecoxib | Celecoxib | 74 | 22 |
| Ipratropium Bromide | Ipratropium Bromide | 74 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 69 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 66 | 19 |
| Lorazepam | Lorazepam | 62 | 13 |
| Mounjaro | Tirzepatide | 62 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 62 | 30 |
| Spironolactone | Spironolactone | 61 | 19 |
| Valacyclovir | Valacyclovir Hcl | 61 | 22 |
| Synthroid | Levothyroxine Sodium | 60 | 13 |
| Pregabalin | Pregabalin | 55 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 54 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 15 |
| Donepezil Hcl | Donepezil Hcl | 51 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 12 |
| Chlorthalidone | Chlorthalidone | 48 | 13 |
| Memantine Hcl | Memantine Hcl | 46 | suppressed |
| Valsartan | Valsartan | 46 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 45 | 15 |
| Mirtazapine | Mirtazapine | 43 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | 12 |
| Atenolol | Atenolol | 39 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 39 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 38 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 38 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Verapamil Er | Verapamil Hcl | 38 | suppressed |
| Famotidine | Famotidine | 36 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 35 | suppressed |
| Lamotrigine | Lamotrigine | 34 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 32 | suppressed |
| Clonazepam | Clonazepam | 31 | 13 |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Testosterone | Testosterone | 31 | suppressed |
| Rybelsus | Semaglutide | 30 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 30 | suppressed |
| Linzess | Linaclotide | 29 | suppressed |
| Ramipril | Ramipril | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Cephalexin | Cephalexin | 28 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 22 |
| Glimepiride | Glimepiride | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 26 | 20 |
| Testosterone Cypionate | Testosterone Cypionate | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 23 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Colchicine | Colchicine | 24 | 13 |
| Klor-Con M20 | Potassium Chloride | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 18 |
| Rizatriptan | Rizatriptan Benzoate | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 13 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | 11 |
| Ketoconazole | Ketoconazole | 19 | 12 |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 17 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 11 |
| Diazepam | Diazepam | 15 | suppressed |
| Modafinil | Modafinil | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $460.07 · 19 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, CAPLYTA, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, MOUNJARO, NEXPLANON, OTEZLA, REPATHA, REXULTI, VRAYLAR, Wegovy, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error